Kiadis employee options committed under the Sanofi Offer
This is a press release by Kiadis Pharma N.V.
(“Kiadis”), pursuant to the provisions of Section
5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids
(Besluit openbare biedingen Wft) (the “Decree”) in
connection with the public offer by Sanofi for all the issued and
outstanding ordinary shares in the capital of Kiadis launched on
February 12, 2021 (the “Offer”). The Offer is made
only by means of the offer memorandum approved by the Dutch
Authority for the Financial Markets (Autoriteit Financiële Markten)
on February 10, 2021 and recognized by the Belgian Authority for
the Financial Markets (Autoriteit voor Financiële Diensten en
Markten) on February 11, 2021 (the “Offer
Memorandum”). This announcement does not constitute an
offer, or any solicitation of any offer, to buy or subscribe for
any securities. Capitalized terms used but not defined in this
press release will have the meaning given thereto in the Offer
Memorandum.
Kiadis employee options committed under
the Sanofi Offer48.80% of Fully Diluted share capital now
committed under the Offer
Amsterdam, The Netherlands, April 9,
2021 – Kiadis Pharma N.V. (“Kiadis” or the “Company”)
(Euronext Amsterdam and Brussels: KDS) today
announces that all Kiadis employee options with an exercise price
below the Offer Price are committed under Sanofi’s Offer, resulting
in approximately 48.80% of the Fully Diluted share capital of
Kiadis now being committed under the Offer.
None of the holders of options on ordinary
shares of Kiadis stock or stock appreciation rights under the
Kiadis 2016 Share Option and Stock Appreciation Right Plan with an
exercise price below the Offer Price (“Options”),
decided to opt-out during the opt-out period that ended yesterday.
Therefore, on the terms and subject to the conditions described in
Section 7.9 (Options and SARs) of the Offer Memorandum, the
7,446,147 ordinary shares of Kiadis stock resulting from the
exercise of such Options are now committed under the Offer, which
is approximately 12.20% of the issued and outstanding ordinary
shares of Kiadis stock (on a Fully Diluted basis).
Together with the irrevocable undertakings given
by (i) Empery Asset Master Ltd., Empery Tax Efficient, LP and
Empery Tax Efficient III, LP; (ii) funds managed by Life Sciences
Partners; (iii) former CytoSen Therapeutics Inc. shareholders and
option holders; and (iv) Kreos Capital V (UK) Limited,
approximately 48.80% of the issued and outstanding ordinary shares
of Kiadis stock, calculated on a Fully Diluted basis, are now
committed under the Offer.
HIERONDER VOLGT EEN VERTALING VAN HET
OORSPRONKELIJK IN DE ENGELSE TAAL OPGESTELDE PERSBERICHT EN DEZE
VERTALING WORDT UITSLUITEND VOOR INFORMATIEVE DOELEINDEN VERSTREKT.
IN GEVAL VAN VERSCHILLEN TUSSEN BEIDE VERSIES PREVALEERT DE ENGELSE
TEKST. AAN DE VERTALING KUNNEN GEEN RECHTEN WORDEN
ONTLEEND
Kiadis personeelsopties toegezegd onder
het Sanofi bod48.80% van het aandelenkapitaal op volledig
verwaterde basis is nu toegezegd onder het Bod
Amsterdam, Nederland, 9 april
2021 – Kiadis Pharma N.V. (‘’Kiadis’’ of de
‘’Vennootschap’’) (Euronext Amsterdam en Brussel:
KDS) kondigt vandaag aan dat alle Kiadis-personeelsopties
met een uitoefenprijs onder de Biedprijs zijn toegezegd onder
Sanofi’s bod, wat ertoe leidt dat ongeveer 48,80% van het totale
aantal aandelen in het kapitaal van Kiadis op volledig verwaterde
basis nu is toegezegd onder het Bod.
Geen van de houders van opties op gewone
aandelen in het kapitaal van Kiadis of aandelen appreciatie rechten
zoals bedoeld in het Kiadis 2016 Aandelenoptie- en Aandelen
Appreciatie Recht Plan met een uitoefenprijs onder de Biedprijs
(‘’Opties’’), heeft besloten zich af te melden
binnen de - gisteren geëindigde – opt-outtermijn. Daarom zijn,
onder de voorwaarden zoals beschreven in hoofdstuk 7.9 (Opties en
SAR’s) van het Biedingsbericht, de 7.446.147 gewone aandelen in het
kapitaal van Kiadis die voortvloeien uit de uitoefening van
dergelijke Opties nu toegezegd onder het Bod, hetgeen ongeveer
12.20% van de uitgegeven en uitstaande gewone aandelen in het
kapitaal van Kiadis (op volledig verwaterde basis) omvat.
Samen met de onherroepelijke toezeggingen van
(i) Empery Asset Master Ltd., Empery Tax Efficient, LP en Empery
Tax Efficient III, LP; (ii) fondsen beheerd door Life Sciences
Partners; (iii) voormalig aandeelhouders en optiehouders van
CytoSen Therapeutics Inc. en (iv) Kreos Capital V (VK) Limited,
zijn ongeveer 48,80% van de uitgegeven en uitstaande gewone
aandelen in het kapitaal van Kiadis, berekend op een volledig
verwaterde basis, nu toegezegd onder het Bod.
For information on the Offer including the Offer
Memorandum and Position Statement, please visit:
https://ir.kiadis.com/sanofi.
For more information:
Kiadis: Maryann
Cimino, Director Investor Relations & Corporate Affairs Tel: +1
617 710-7305 m.cimino@kiadis.com |
Kiadis Media Relations
ContactsLifeSpring Life Sciences
Communication: Leon Melens (Amsterdam) Tel: +31 6 538 16
427 lmelens@lifespring.nlOptimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
|
|
About Kiadis
Founded in 1997, Kiadis is committed to
developing innovative cell-based medicines for patients with
life-threatening diseases. With headquarters in Amsterdam, The
Netherlands, and offices and activities across the United States,
Kiadis is reimagining medicine by leveraging the natural strengths
of humanity and our collective immune system to source the best
cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.Kiadis.com.
Kiadis Forward-Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis’ or, as
appropriate, Kiadis’ officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis expressly disclaims any obligation or
undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.